1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. Company
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Delayed Xetra  -  05/20 11:36:09 am EDT
1.060 EUR    0.00%
05/19TRANSCRIPT : Biofrontera AG, Q1 2022 Earnings Call, May 19, 2022
CI
05/17Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/13Earnings Flash (BFRI) BIOFRONTERA Posts Q1 Revenue $9.8M, vs. Street Est of $9.83M
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

Number of employees : 99 people.
Sales per Business
20202021Delta
Dermatological Medications and Medical Cosmetics30.35100%28.79100% -5.14%
EUR in Million
Sales per region
20202021Delta
United States16.5954.7%20.2070.3% +21.79%
Germany5.1617%5.2618.3% +2.02%
Europe2.106.9%3.2711.4% +55.42%
EUR in Million
Managers
Name Title Age Since
Ludwig Lutter Chief Financial Officer 54 2021
Pamela Keck Investor Relations Contact 40 2018
Members of the board
Name Title Age Since
Wilhelm Konrad Zours Chairman-Supervisory Board 60 2021
Heikki Lanckriet, Dr. Member-Supervisory Board 44 2021
Helge Lubenow, Dr. Member-Supervisory Board 53 2021
Karlheinz Schmelig Member-Supervisory Board - 2021
J÷rgen Thielmann Vice Chairman-Supervisory Board - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 56,717,385 26,322,538 46.4% 0 0.0% 46.4%
Shareholders
NameEquities%
Deutsche Balaton AG 14,605,893 25.8%
Maruho Co., Ltd. 13,399,965 23.6%
Wilhelm Konrad Zours 6,571,784 11.6%
Sparta AG 3,215,000 5.67%
AWM Investment Co., Inc. 821,781 1.45%
Hermann LŘbbert 348,000 0.61%
Matejka & Partner Asset Management GmbH 109,734 0.19%
Baader Bank AG (Investment Management) 35,000 0.062%
SMS & Cie. Verm÷gensmanagement GmbH 25,000 0.044%
Banque Degroof Petercam Luxembourg SA 19,881 0.035%
Holdings
NameEquities%Valuation
BIOFRONTERA INC. (BFRI) 8,000,000 46.8% 29,600,000 USD
Company contact information
Biofrontera AG
Hemmelrather Weg 201
Leverkusen, Nordrhein-Westfalen 51377

Phone : +49.214.87.63.2.0
Fax : +49.214.87.63.2.90
Web : http://biofrontera.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Biofrontera AG